Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells

被引:9
作者
Blom, DJR
Goslings, WRO
DeWaardSiebinga, I
Luyten, GPM
Claas, FHJ
Gorter, A
Jager, MJ
机构
[1] LEIDEN UNIV,MED CTR,DEPT IMMUNOHAEMATOL,NL-2300 RC LEIDEN,NETHERLANDS
[2] LEIDEN UNIV,MED CTR,DEPT PATHOL,NL-2300 RC LEIDEN,NETHERLANDS
[3] UNIV ROTTERDAM HOSP,DEPT OPHTHALMOL,ROTTERDAM,NETHERLANDS
关键词
D O I
10.1089/jir.1997.17.695
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor cells are protected from antibody-dependent complement-mediated lysis by membrane-bound regulators of complement activation (m-RCA). m-RCA are expressed on uveal melanoma cells. We determined whether cytokine treatment affects expression of m-RCA on these cells in vitro. m-RCA expression on uveal melanoma cell lines was studied by flow cytometry, using monoclonal antibodies directed against CD46, CD55, and CD59. Cytokines studied were interferon-alpha (IFN-alpha), IFN-gamma, interleukin-1B (IL-1B), 1L-12, and tumor necrosis factor-alpha (TNF-alpha). All three m-RCA were expressed on the uveal melanoma cell lines (CD59>>CD46>CD55), although in variable amounts, With a few exceptions, the cytokines had no effect on m-RCA expression. CD55 expression was not influenced by any of the cytokines. IFN-gamma downregulated expression of CD46 on one cell line (p < 0.01). TNF-alpha upregulated CD59 expression on two of the five cell lines (p < 0.012 and p < 0.001, respectively), which effect was dose dependent, IFN-alpha, IFN-gamma, IL1-beta, IL12, and TNF-alpha had limited effects on m-RCA expression on uveal melanoma cells in vitro,
引用
收藏
页码:695 / 700
页数:6
相关论文
共 15 条
[1]   INTERFERONS IN THE THERAPY OF SOLID TUMORS [J].
AGARWALA, SS ;
KIRKWOOD, JM .
ONCOLOGY, 1994, 51 (02) :129-136
[2]  
Bishop JAN, 1996, CANCER SURV, V26, P321
[3]   THE INFLUENCE OF TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA AND INTERFERON-GAMMA ON THE EXPRESSION AND FUNCTION OF THE COMPLEMENT REGULATORY PROTEIN CD59 ON THE HUMAN COLONIC ADENOCARCINOMA CELL-LINE HT29 [J].
BJORGE, L ;
JENSEN, TS ;
ULVESTAD, E ;
VEDELER, CA ;
MATRE, R .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (04) :350-356
[4]  
BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
[5]   EXPRESSION OF PROTECTIN (CD59) IN HUMAN-MELANOMA AND ITS FUNCTIONAL-ROLE IN CELL-MEDIATED AND COMPLEMENT-MEDIATED CYTOTOXICITY [J].
BRASOVEANU, LI ;
ALTOMONTE, M ;
GLOGHINI, A ;
FONSATTI, E ;
CORAL, S ;
GASPAROLLO, A ;
MONTAGNER, R ;
CATTAROSSI, I ;
SIMONELLI, C ;
CATTELAN, A ;
ATTADIA, V ;
CARBONE, A ;
MAIO, M .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (04) :548-556
[6]   CYTOKINE-MEDIATED MODULATION OF INTEGRIN, ICAM-1 AND CD44 EXPRESSION ON HUMAN UVEAL MELANOMA-CELLS IN-VITRO [J].
CREYGHTON, WM ;
DEWAARDSIEBINGA, I ;
DANEN, EHJ ;
LUYTEN, GPM ;
VANMUIJEN, GNP ;
JAGER, MJ .
MELANOMA RESEARCH, 1995, 5 (04) :235-242
[7]   EFFECTS OF INTERFERON-ALFA AND INTERFERON-GAMMA ON HUMAN UVEAL MELANOMA-CELLS IN-VITRO [J].
DEWAARDSIEBINGA, I ;
CREYGHTON, WM ;
KOOL, J ;
JAGER, MJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (09) :847-855
[8]   TUMOR-ASSOCIATED ANTIBODIES IN THE SERUM OF PATIENTS WITH OCULAR MELANOMA .3. IMMUNOPEROXIDASE DETECTION [J].
FELBERG, NT ;
PROLANDAZURI, JM ;
SHIELDS, JA ;
FEDERMAN, JL .
ARCHIVES OF OPHTHALMOLOGY, 1979, 97 (02) :256-259
[9]   Interleukin-12: Potential clinical applications in the treatment and prevention of infectious diseases [J].
Gately, MK ;
Mulqueen, MJ .
DRUGS, 1996, 52 :18-25
[10]  
Gorter A, 1996, LAB INVEST, V74, P1039